

# 7<sup>TH</sup> ACUTE LEUKAEMIA DAY

## Dilemmas and Daily Challenges

Friday 22<sup>nd</sup> September 2017

BMA House, Tavistock Square, Bloomsbury, London WC1H 9JP

Chair: Professor Charles Craddock (*Birmingham*)

Co-Chairs: Dr Mike Dennis (*Manchester*) and Dr Andrew McMillan (*Nottingham*)

09:30 Registration

Spotlight on ALL		
10:00	Overview of new ALL trials	Dr Sridhar Chaganti ( <i>Birmingham</i> )
10:30	How should we manage adult Philadelphia positive ALL in 2017	Professor Oliver Ottmann ( <i>Cardiff</i> )
10:50	Management of adult lymphoblastic lymphoma: Common pitfalls	Dr Andrew McMillan ( <i>Nottingham</i> )

11:10 Coffee

Plenary Lectures		
11:35	How will molecular medicine improve our treatment of acute leukaemia	Professor Brian Huntly ( <i>Cambridge</i> )
12:00	Improving outcome in adult acute myeloid leukaemia - which strategies show greatest promise in 2017	Professor Charles Craddock ( <i>Birmingham</i> )
Guest Speaker		
12:25	Immunotherapy in acute leukaemias	Professor John Barrett ( <i>Bethesda, USA</i> )

13:00 Lunch

Spotlight on AML		Nurses Parallel Session											
13:45	NCRN trials in AML – update Professor Nigel Russell ( <i>Nottingham</i> )	13:30	Transplant in acute leukaemia – nursing issues pre, post and beyond Michelle Kenyon ( <i>London</i> )										
14:10	Transplantation in AML Dr Rachel Protheroe ( <i>Bristol</i> )												
Controversy in T-ALL		Nurses Workshops											
14:30	Treatment options in adult T-ALL- what have we learnt? Dr Eduardo Olavarria ( <i>Hammersmith</i> )	14:00	<table border="1"> <thead> <tr> <th>ALL</th> <th>AML</th> </tr> </thead> <tbody> <tr> <td><b>Run by:</b> Orla Stewart (<i>King's</i>)</td> <td><b>Run by:</b> Flora Dangwa (<i>UCLH</i>)</td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>➤ Patient perspective Paul Philips</li> </ul> </td> <td>Case studies for discussion:</td> </tr> <tr> <td><b>Discussion points:</b></td> <td><b>High risk AML</b></td> </tr> <tr> <td> <ul style="list-style-type: none"> <li>➤ Nursing challenges of managing ALL</li> <li>➤ Novel therapies including CAR T</li> </ul> </td> <td>Other</td> </tr> </tbody> </table>	ALL	AML	<b>Run by:</b> Orla Stewart ( <i>King's</i> )	<b>Run by:</b> Flora Dangwa ( <i>UCLH</i> )	<ul style="list-style-type: none"> <li>➤ Patient perspective Paul Philips</li> </ul>	Case studies for discussion:	<b>Discussion points:</b>	<b>High risk AML</b>	<ul style="list-style-type: none"> <li>➤ Nursing challenges of managing ALL</li> <li>➤ Novel therapies including CAR T</li> </ul>	Other
ALL	AML												
<b>Run by:</b> Orla Stewart ( <i>King's</i> )	<b>Run by:</b> Flora Dangwa ( <i>UCLH</i> )												
<ul style="list-style-type: none"> <li>➤ Patient perspective Paul Philips</li> </ul>	Case studies for discussion:												
<b>Discussion points:</b>	<b>High risk AML</b>												
<ul style="list-style-type: none"> <li>➤ Nursing challenges of managing ALL</li> <li>➤ Novel therapies including CAR T</li> </ul>	Other												
Debate in AML													
14:50	Allogeneic SCT should be considered standard of care in fit adults over 55 years of age  <b>For:</b> Professor Jamie Cavenagh ( <i>London</i> )  <b>Against:</b> Professor Robert Hills ( <i>Cardiff</i> )												

15:20 Coffee

Please turn over

Meet the Experts Breakouts			
	AML	ALL	Trials
15:40	Dr Mike Dennis ( <i>Manchester</i> )  ♦ Management of relapsed and refractory AML in the real world	Dr Debby Yallop ( <i>London</i> )  ♦ Management of ALL in older patients ♦ Cases	Mr Ian Thomas & Dr Sophie Betteridge ( <i>Cardiff</i> )  ♦ How CTUs can support participating sites to deliver trials

16:30 Meeting Close

#### REGISTRATION FEES:

	Consultants	Trainees/Nurses/Others
<b>Early Bird:</b> Until Thursday 31 <sup>st</sup> August	£144 (inc VAT)	£60 (inc VAT)
<b>Late Registration:</b> From 1 <sup>st</sup> September	£180 (inc VAT)	£120 (inc VAT)

Register online at [www.hartleytaylor.co.uk](http://www.hartleytaylor.co.uk).

Enquiries: [alex@hartleytaylor.co.uk](mailto:alex@hartleytaylor.co.uk) or telephone 01565 621967

#### Major Sponsors:



#### Sponsors:



Endorsed by **Bloodwise**  
Beating blood cancer since 1960

*The sponsors have had no influence over the content of the agenda or speaker selection*